Zosano Pharma Corporation (NASDAQ:ZSAN) was downgraded by investment analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a research report issued to clients and investors on Monday, July 24th.
Shares of Zosano Pharma Corporation (NASDAQ ZSAN) traded down 9.57% during midday trading on Monday, hitting $0.85. 1,362,502 shares of the company were exchanged. Zosano Pharma Corporation has a one year low of $0.45 and a one year high of $3.54. The company’s market capitalization is $33.32 million. The company has a 50-day moving average of $1.28 and a 200 day moving average of $1.58.
Zosano Pharma Corporation (NASDAQ:ZSAN) last posted its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.17) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by $0.02. During the same period last year, the company earned ($0.54) EPS. On average, equities research analysts expect that Zosano Pharma Corporation will post ($0.97) earnings per share for the current fiscal year.
WARNING: This report was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://stocknewstimes.com/2017/08/12/zosano-pharma-corporation-nasdaqzsan-cut-to-strong-sell-at-valuengine-updated-updated.html.
In other Zosano Pharma Corporation news, CFO Georgia Erbez bought 68,000 shares of the stock in a transaction on Thursday, May 25th. The stock was purchased at an average price of $1.32 per share, with a total value of $89,760.00. Following the completion of the purchase, the chief financial officer now owns 115,750 shares in the company, valued at $152,790. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO John Peter Walker bought 73,716 shares of the stock in a transaction on Thursday, May 25th. The shares were acquired at an average cost of $1.36 per share, with a total value of $100,253.76. Following the purchase, the chief executive officer now owns 169,344 shares of the company’s stock, valued at approximately $230,307.84. The disclosure for this purchase can be found here. Corporate insiders own 2.95% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of ZSAN. Northern Trust Corp increased its position in shares of Zosano Pharma Corporation by 591.4% in the second quarter. Northern Trust Corp now owns 79,234 shares of the biotechnology company’s stock valued at $112,000 after buying an additional 67,774 shares during the last quarter. Granite Point Capital Management L.P. acquired a new position in shares of Zosano Pharma Corporation during the first quarter valued at approximately $285,000. Victory Capital Management Inc. acquired a new position in shares of Zosano Pharma Corporation during the first quarter valued at approximately $449,000. Nexthera Capital LP acquired a new position in shares of Zosano Pharma Corporation during the first quarter valued at approximately $950,000. Finally, Perceptive Advisors LLC acquired a new position in shares of Zosano Pharma Corporation during the first quarter valued at approximately $950,000. 24.03% of the stock is owned by hedge funds and other institutional investors.
Zosano Pharma Corporation Company Profile
Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Zosano Pharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma Corporation and related companies with MarketBeat.com's FREE daily email newsletter.